Anti-phospholipid syndrome in seven leprosy patients with thrombotic events on corticosteroid and/or thalidomide regimen: insights on genetic and laboratory profiles
Rev. Soc. Bras. Med. Trop
;
51(1): 99-104, Jan.-Feb. 2018. tab, graf
Article
in English
| LILACS
| ID: biblio-1041441
ABSTRACT
Abstract INTRODUCTION Corticosteroids and/or thalidomides have been associated with thromboembolism events (TBE) in multibacillary (MB) leprosy. This report aimed to determine genetic and laboratory profiles associated with leprosy and TBE. METHODS Antiphospholipid antibodies (aPL), coagulation-related exams, prothrombin and Leiden's factor V mutations, and ß2-glycoprotein-I (ß2GPI) Val247Leu polymorphism were assessed. RESULTS Six out of seven patients with leprosy were treated with prednisone and/or thalidomide during TBE and presented at least one positive aPL. All patients presented ß2GPI polymorphism, and one showed prothrombin mutation. CONCLUSIONS Corticosteroid or thalidomide adverse effects and aPL and ß2GPI polymorphisms may cause TBE in patients with MB leprosy.
Full text:
Available
Index:
LILACS (Americas)
Main subject:
Thalidomide
/
Antiphospholipid Syndrome
/
Adrenal Cortex Hormones
/
Leprosy, Multibacillary
Limits:
Adolescent
/
Aged
/
Female
/
Humans
/
Male
Language:
English
Journal:
Rev. Soc. Bras. Med. Trop
Journal subject:
Tropical Medicine
Year:
2018
Type:
Article
Affiliation country:
Brazil
Institution/Affiliation country:
Universidade de São Paulo/BR
Similar
MEDLINE
...
LILACS
LIS